Viewing Study NCT06253650

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:19 PM
Ignite Modification Date: 2026-02-01 @ 1:25 PM
Study NCT ID: NCT06253650
Status: RECRUITING
Last Update Posted: 2024-06-13
First Post: 2024-02-02
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Sponsor: Gruppo Oncologico del Nord-Ovest
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Gastric Cancer View
None HER2-positive Gastric Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Trastuzumab-Deruxtecan View
None Gastric Cancer View
None HER2-positive Gastric Cancer View
None Liquid biopsy View
None Minimal residual disease View